A structural perspective on targeting the RTK/Ras/MAP kinase pathway in cancer.

ABSTRACT: Precision oncology is premised on identifying and drugging proteins and pathways that drive tumorigenesis or are required for survival of tumor cells. Across diverse cancer types, the signaling pathway emanating from receptor tyrosine kinases on the cell surface to RAS and the MAP kinase pathway is the most frequent target of oncogenic mutations, and key proteins in this signaling axis including EGFR, SHP2, RAS, BRAF, and MEK have long been a focus in cancer drug discovery. In this review, we provide an overview of historical and recent efforts to develop inhibitors targeting these nodes with an emphasis on the role that an understanding of protein structure and regulation has played in inhibitor discovery and characterization. Beyond its well-established role in structure-based drug desig

SUBMITTER: Heppner DE 

PROVIDER: S-EPMC8284588 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature